1. Home
  2. RVLV vs BBIO Comparison

RVLV vs BBIO Comparison

Compare RVLV & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

HOLD

Current Price

$31.19

Market Cap

2.1B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$74.32

Market Cap

14.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVLV
BBIO
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
14.7B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
RVLV
BBIO
Price
$31.19
$74.32
Analyst Decision
Buy
Strong Buy
Analyst Count
13
21
Target Price
$27.08
$78.71
AVG Volume (30 Days)
1.0M
1.9M
Earning Date
02-24-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
35.78
N/A
EPS
0.78
N/A
Revenue
$1,195,039,000.00
$353,780,000.00
Revenue This Year
$8.95
$127.64
Revenue Next Year
$6.42
$78.38
P/E Ratio
$40.36
N/A
Revenue Growth
9.24
62.46
52 Week Low
$16.80
$28.10
52 Week High
$33.68
$78.59

Technical Indicators

Market Signals
Indicator
RVLV
BBIO
Relative Strength Index (RSI) 67.62 51.53
Support Level $29.56 $71.19
Resistance Level $31.48 $75.57
Average True Range (ATR) 1.05 2.44
MACD -0.07 -0.65
Stochastic Oscillator 86.49 38.54

Price Performance

Historical Comparison
RVLV
BBIO

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: